Payment overview · 2025
General Payments
$128.65
6 reported records · 5 companies
Healthcare provider profile · identity verified
Daniel A Buckingham, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OAKLAND, MD · NPI 1992732028
Verified facts
What the public records show
CMS Open Payments records show Daniel A Buckingham, M.D. received $128.65 in general payments during 2025 across 6 reported records.
HARMONY BIOSCIENCES LLC accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $48.99 | 38.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.06 | 24.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.50 | 13.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.03 | 12.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.07 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.65 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $48.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 271 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 70 |
| Tramadol Hcl | Tramadol Hcl | 203 | 37 |
| Lisinopril | Lisinopril | 195 | 55 |
| Omeprazole | Omeprazole | 161 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 51 |
| Gabapentin | Gabapentin | 151 | 40 |
| Pregabalin | Pregabalin | 125 | 19 |
| Metformin Hcl | Metformin Hcl | 124 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 38 |
| Simvastatin | Simvastatin | 117 | 34 |
| Furosemide | Furosemide | 113 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 32 |
| Alprazolam | Alprazolam | 106 | 16 |
| Losartan Potassium | Losartan Potassium | 105 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 29 |
| Potassium Chloride | Potassium Chloride | 98 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 19 |
| Metformin Hcl Er | Metformin Hcl | 90 | 22 |
| Eliquis | Apixaban | 87 | 22 |
| Clonazepam | Clonazepam | 83 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 22 |
| Ozempic | Semaglutide | 74 | 16 |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Lorazepam | Lorazepam | 70 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 16 |
| Famotidine | Famotidine | 67 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 20 |
| Celecoxib | Celecoxib | 63 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 23 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 24 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 54 | 15 |
| Atenolol | Atenolol | 53 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Jardiance | Empagliflozin | 52 | 17 |
| Carvedilol | Carvedilol | 51 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 46 | 39 |
| Spironolactone | Spironolactone | 45 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Finasteride | Finasteride | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Prednisone | Prednisone | 35 | 20 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 21 |
| Diazepam | Diazepam | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxaprozin | Oxaprozin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.65 · 6 records | HARMONY BIOSCIENCES LLC | Dexcom G6 Transmitter, GIVLAARI, Ozempic, Rybelsus, WAKIX, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error